{
    "pmcid": "9778468",
    "qa_pairs": {
        "What assay modification is suggested to increase specificity and reduce false positives in serological assays?": [
            "Using a urea wash to remove low-avidity interactions",
            "Increasing the concentration of antigens in the assay",
            "Decreasing the incubation time of the assay",
            "Using a single antigen detection method"
        ],
        "What is the primary cause of cross-reactivity between antibodies generated during malaria infections and the SARS-CoV-2 Spike protein?": [
            "Antibodies targeting sialic acid residues on N-linked glycans of the Spike protein",
            "Antibodies targeting protein epitopes on the Spike protein",
            "Antibodies targeting lipid components of the Spike protein",
            "Antibodies targeting RNA sequences within the Spike protein"
        ],
        "What should therapeutic nanobodies focus on to enhance their potential against SARS-CoV-2?": [
            "Conserved protein epitopes across different SARS-CoV-2 variants",
            "Variable glycan structures on the Spike protein",
            "Lipid components of the viral envelope",
            "RNA sequences within the virus"
        ],
        "What treatment significantly reduces cross-reactivity by removing sialic acids from the SARS-CoV-2 Spike protein?": [
            "Neuraminidase treatment",
            "Protease treatment",
            "Lipase treatment",
            "RNAse treatment"
        ],
        "Why do malaria-induced antibodies not confer protective immunity against SARS-CoV-2 despite cross-reactivity?": [
            "They do not neutralize SARS-CoV-2",
            "They enhance viral entry into host cells",
            "They only bind to non-functional regions of the virus",
            "They are rapidly degraded in the bloodstream"
        ]
    }
}